Physician profile
Niraj Shah
NPI 1386968022
$10,169.56
in general payments reported to CMS, 2019-2025
16 companies · $828 in 2025
The $828 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,630 · 2021: $182 · 2022: $342 · 2023: $688 · 2024: $2,498 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,815 · Consulting Fee: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,815.31 |
| Consulting Fee | $1,200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,320.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $1,403.02 | 2019-2025 | Eylea Hd, Eylea |
| Beaver-Visitec International, INC. | $1,200.00 | 2024 | |
| Alimera Sciences, INC. | $487.89 | 2019-2024 | Iluvien, Yutiq |
| Abbvie INC. | $427.45 | 2022-2025 | Ozurdex |
| Regeneron Pharmaceuticals, INC. | $371.66 | 2022-2025 | Eylea Hd, Eylea |
| Astellas Pharma US INC | $310.87 | 2023-2025 | Izervay |
| Genentech USA, INC. | $221.88 | 2019-2025 | Vabysmo, Susvimo |
| Mallinckrodt Hospital Products INC. | $105.97 | 2021 | |
| Apellis Pharmaceuticals, INC. | $102.50 | 2023-2024 | Syfovre |
| Ani Pharmaceuticals, INC. | $89.64 | 2024-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $33.78 | 2021 | |
| Alcon Vision LLC | $30.69 | 2025 | Unity |
| Tarsus Pharmaceuticals, INC. | $24.71 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $20.25 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $19.25 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.